At Investor Conferences

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in France and Monaco or involving organisations from these countries.

Total search results: 1914 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Carmat–France (govt): grant, 202010– grant €13m national innovation funding for clinical study of artificial heart in France from Health Ministry 2020-10-12
Priothera–Earlybird: investment, 202010 financing round Series A totalling €30m incl co-investor Earlybird Venture Capital 2020-10-12
Priothera–Fountain Healthcare Partners: investment, 202010 financing round Series A totalling €30m incl lead investor FHP 2020-10-12
Priothera–Huntsworth: public relations, 202010 service existent by Citigate Dewe Rogerson 2020-10-12
Priothera–Kyorin: mocravimod, 202010c acquisition of mocravimod from Kyorin Pharmaceutical Co Ltd 2020-10-12
Priothera–Odlander Fredrikson: investment, 202010 financing round Series A totalling €30m incl co-lead investor HealthCap 2020-10-12
Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners 2020-10-12
Priothera–Tekla Capital: investment, 202010 financing round Series A totalling €30m incl co-investor funds managed by Tekla Capital Management LLC 2020-10-12
Federation Bio–BPCE: investment, 202010 financing round Series A totalling $50m incl new + co-investor Seventure Partners/Health for Life Capital 2020-10-06
Federation Bio–SEVERAL: investment, 202010 financing round Series A $50m led by Horizons Ventures + incl Seventure Partners + Venrock + Altitude 2020-10-06
Novartis–Merck (DE): Nanobodies, 202010– license €50m upfront + €400m milestones to M6495 anti-ADAMTS5 Nanobody for osteoarthritis 2020-10-06
BIA Separations–Sartorius: investment, 202010– acquisition €240m in cash + €120m in SSB shares BIA to be merged into SSB ANNOUNCED 2020-10-02
Sophia Genetics–Eurazeo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Eurazeo Growth 2020-10-01
Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Venturse 2020-09-25
Bellevue–SEVERAL: investment, 202009 Closing $170m of BB Pureos Bioventures LP fund 2020-09-23
Lava Therapeutics–Sanofi: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Sanofi Ventures 2020-09-17
ImCheck Therapeutics–Bellevue: investment, 202009 financing round Series B extension €6m from BB Pureos Bioventures bringing total Series B to €54m 2020-09-15
Evotec–BIOASTER: antiinfectives, 202009– collab research to establish tech + innovation hub in Lyon work started in early 2020 2020-09-14
Neogene Therapeutics–Jeito Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Jeito Capital 2020-09-14
Neogene Therapeutics–SEVERAL: investment, 202009 financing round Series A $110m co-led by EcorR1 Capital + Jeito Capital + Syncona 2020-09-14
Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares 2020-08-19
Principia Biopharma–Sanofi: investment, 202008– acquisition $3.68b cash tender offer at $100/share 2020-08-17
Genkyotex–Calliditas Therapeutics: investment, 202008– acquisition in two steps for €32.3m in cash + €55m milestones (contingent rights) ANNOUNCED 2020-08-13
T-Knife–SEVERAL: investment, 202008 financing round Series A €66m co-led by Versant Ventures + RA Capital 2020-08-06
DNA Script–SEVERAL: investment, 202007 financing round Series B extension $50m led by Casdin Capital 2020-07-29
Enthera–SEVERAL: investment, 202007 financing round Series A €28m co-led by Sofinnova Partners + AbbVie Ventures 2020-07-28
Enthera–Sofinnova: investment, 202007 financing round Series A totalling €28m incl existing + co-lead investor Sofinnova Partners 2020-07-28
Tubulis–BPCE: investment, 202007 financing round Series A totalling €10.7m incl co-investor Seventure Partners 2020-07-21
Tubulis–SEVERAL: investment, 202007 financing round Series A €10.7m co-led by BioMedPartners + HTGF 2020-07-21
Enancio–Illumina: acquisition, 202007 acquisition of Enancio by Illumina 2020-07-14
Osivax–Trophic Communications: public relations, 202007 service existent by Trophic Communications 2020-07-08
Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties 2020-07-08
Citryll–BPCE: investment, 202007 financing round Series A totalling €18.5m incl new + lead investor Seventure incl its Health for Capital II fund 2020-07-02
Citryll–SEVERAL: investment, 202007 financing round Series A €18.5m led by Seventure + co-led by BioGeneration Ventures 2020-07-02
Lysogene–Weizmann Institute: gene therapy, 202007– collab research + license option AAV gene therapy for Gaucher + Parkinson diseases 2020-07-01
Resolution Spectra Systems–Merck (DE): investment, 202007 acquisition €na of Resolution Spectra Systems by Merck 2020-07-01
Enterome–BPCE: investment, 202006 financing round Series E €na incl existing investor Seventure Health for Life Capital 2020-06-25
Enterome–Nestlé: investment, 202006 financing round Series E €na incl existing investor Nestlé Health Science 2020-06-25
Enterome–Omnes Capital: investment, 202006 financing round Series E €na incl existing investor Omnes Capital 2020-06-25
Enterome–Principia SGR: investment, 202006 financing round Series E €na incl existing investor Principia 2020-06-25
Enterome–SEVERAL: investment, 202006 financing round Series E €na with existing plus new investors SymBiosis LLC + Takeda Pharma 2020-06-25
Enterome–SymBiosis LLC: investment, 202006 financing round Series E €na incl new investor SymBiosis LLC 2020-06-25
Enterome–Takeda: investment, 202006 financing round Series E €na incl new investor Takeda Pharmaceutical Co Ltd 2020-06-25
RareCyte–Scienion: single-cell dispenser, 202006 supply existent of cellenONE to RareCyte for CTC analysis technology by Cellenion 2020-06-22
DiogenX–Advent France Biotechnology: investment, 202006 seed financing round totalling €4.5m incl investor Advent France Biotechnology 2020-06-16
DiogenX–Andrew Lloyd Associates: public relations, 202006 service existent by ALA 2020-06-16
DiogenX–Boehringer: investment, 202006 seed financing round totalling €4.5m incl investor BIVF 2020-06-16
DiogenX–Juvenile Diabetes Research Foundation: investment, 202006 seed financing round totalling €4.5m incl investor JDRF T1D Fund 2020-06-16
DiogenX–SEVERAL: investment, 202006 seed financing round €4.5m from Advent France Biotechnology + BIVF + JDRF T1D Fund 2020-06-16
eTheRNA–BNP Paribas: investment, 202006 financing round Series B totalling €34m incl new investor BNP Paribas Fortis Equity 2020-06-16
MedinCell–SEVERAL: investment, 202006 capital increase €15.6m from French + international investors 2020-06-16
Ona Therapeutics–France (govt): investment, 202006 financing round Series A totalling €30m incl new investor Bpifrance InnoBio 2 2020-06-16
Ona Therapeutics–SEVERAL: investment, 202006 financing round Series A €30m 2020-06-16
Epsilen Bio–Sofinnova: investment, 202006c seed financing €2.3m from Sofinnova Partners through Sofinnova Telethon Fund 2020-06-15
Corvidia Therapeutics–Novo Group: investment, 202006 acquisition $725m upfront cash + $1.375b milestones cash by Novo Nordisk ANNOUNCED 2020-06-11
Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Belfius Insurance 2020-06-10
Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor FPIM 2020-06-10
Bioqube Ventures–EU (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor EIF 2020-06-10
Bioqube Ventures–Flanders (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor PMV 2020-06-10
Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab 2020-06-10
Bioqube Ventures–JnJ: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor JnJ Innovation 2020-06-10
Bioqube Ventures–Molenwater Groep: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Molenwater Groep 2020-06-10
Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al 2020-06-10
Protera–SEVERAL: investment, 202006 financing round Series A $5.6m led by Sofinnova Partners + incl existing investor SOSV 2020-06-10
NodThera–SEVERAL: investment, 202006 financing round Series B £44m ($55m) led by Novo Ventures 2020-06-03
MedinCell–SEVERAL: credit, 202005– state guaranteed PGE loan €10.9m at 0.25% up to 5y from Banque Populaire du Sud + BNP Paribas 2020-05-27
Tollys–Andrew Lloyd Associates: public relations, 202005 service existent by ALA 2020-05-26
Tollys–SEVERAL: investment, 202005 financing round Series A €2.3m bringing total raised since founding 2015 to €6.4m 2020-05-26
Poxel–Trophic Communications: public relations, 202005 service existent IR+ media EU/US by Trophic Communications 2020-05-25
Regeneron–Sanofi: investment, 202005 DIVESTMENT $11.7b of 22.8m shares at $515/share with Sanofi retaining 400k shares 2020-05-25
HotSpot Therapeutics–SEVERAL: investment, 202005 financing round Series B $65m led by SR One 2020-05-21
HotSpot Therapeutics–Sofinnova: investment, 202005 financing round Series B totalling $65m incl existing + co-investor Sofinnova Partners 2020-05-21
Genespire–San Raffaele: gene therapy, 2002005– collab strategic alliance development of gene therapies with SR-Tiget 2020-05-13
ElsaLys–Mediolanum: investment, 202005 acquisition of ElsaLys Biotech by Mediolanum Farmaceutici SpA 2020-05-07
Vaxxel–Transgene: cell line technology, 202005 acquisition €na of DuckCelt-T17 cell line from Transgene incl shareholding for Transgene 2020-05-04
Vaxxel–Transgene: investment, 202005 investment €na Transgene becomes shareholder as part of acquisition of DuckCelt-T17 cell line by Vaxxel 2020-05-04
Lifebit–Eurazeo: investment, 202004 financing round Series totalling £6m incl new + lead investor Idinvest Partners 2020-04-30
Lifebit–SEVERAL: investment, 202004 financing round Series £6m led by new investor Idinvest Partners 2020-04-30
Pfizer–Valneva: Lyme disese vaccine, 202004– collab developm of VLA15 + commerc by Pfizer $130m upfront + $178m milestones + 2-digit tiered royalties 2020-04-30
PinCell–SEVERAL: investment, 202004 seed financing round €1.65m led by Sofinnova Telethon Fund 2020-04-30
PinCell–Sofinnova: investment, 202004 seed financing round totalling €1.65m incl lead investor Sofinnova Telethon Fund 2020-04-30
Genespire–Sofinnova: investment, 202004 Series A financing €16m from Sofinnova Partners 2020-04-29
Kurma–EU (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor EIF 2020-04-29
Kurma–Institut Pasteur: investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor Pasteur Institute 2020-04-29
Kurma–North Rhine-Westphalia (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor NRW.BANK 2020-04-29
Kurma–SEVERAL: investment, 202004 final closing of Kurma Biofund III with €160m 2020-04-29
MicroPort Scientific–Robocath: cardiovascular devices, 202004– collab strategic agreem to set up joint venture in China for vascular robotics platform 2020-04-29
Polyplus-transfection–Warburg Pincus: investment, 202004 investment resulting in Warburg Pincus + ArchiMed owning equal shares + voting rights 2020-04-29
Robocath–MicroPort Scientific: investment, 202004 financing round Series C totalling €40m incl new + lead investor MicroPort Scientific Corp 2020-04-29
Robocath–SEVERAL: investment, 202004 financing round Series C €40m led by MicroPort Scientific 2020-04-29
Gustave Roussy–Biognosys: MS-based proteomics, 202004– collab using proteomic profiling in attempt to repurpose tocilizumab for Covid-19 2020-04-28
BrainVectis–AskBio: investment, 202004 acquisition €na of BrainVectis by Asklepios BioPharmaceutical 2020-04-22
EnginZyme–SEVERAL: investment, 202004 financing round Series A €6.4m led by Sofinnova Partners 2020-04-22
EnginZyme–Sofinnova: investment, 202004 financing round Series A totalling €6.4m incl lead investor Sofinnova Industrial Biotech Fund 2020-04-22
Valneva–Dynavax: SARS-CoV-2 vaccine, 202004– collab development combining Valneva’s vaccine technology with adjuvant CpG 1018 of Dynavax 2020-04-22
LNC Therapeutics–Univ Valencia: microbiomic treatment, 202004– license ww excl for patent on Christensenella therapeutics for mood disorders 2020-04-15
Servier–Gorrissen Federspiel: legal services, 202004 supply service Gorrissen Federspiel legal advisor to Servier w regard to acquisition of Symphogen 2020-04-03
Servier–Lazard: financial services, 202004 supply service Lazard financial advisor to Servier w regard to acquisition of Symphogen 2020-04-03
Servier–McDermott Will & Emery: legal services, 202004 supply service MWE legal advisor to Servier w regard to acquisition of Symphogen 2020-04-03
Symphogen–Perkins Coie: legal services, 202004 supply service Perkins Coie legal advisor to Symphogen w regard to acquisition by Servier 2020-04-03
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  next pagenext page



Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] Made Without Love 650x80px

» top